UK markets open in 51 minutes
NIKKEI 225
39,106.59 +489.49 (+1.27%) HANG SENG
18,844.55 -351.05 (-1.83%) CRUDE OIL
76.94 -0.63 (-0.81%) GOLD FUTURES
2,361.60 -31.30 (-1.31%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,547.95 -469.67 (-0.85%)
Abbott Laboratories (ABTCL.SN)
Santiago - Santiago Delayed price. Currency in CLP
Add to watchlist
At close: 01:01PM CLT
| Previous close | 108,200.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 105,680.00 - 105,680.00 |
| 52-week range | 81,085.00 - 117,270.00 |
| Volume | |
| Avg. volume | 3 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | 24,531.10 |
| EPS (TTM) | 4.31 |
| Earnings date | 18 Jul 2024 - 22 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
Simply Wall St.We Think Some Shareholders May Hesitate To Increase Abbott Laboratories' (NYSE:ABT) CEO Compensation
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford...
- Simply Wall St.
Results: Abbott Laboratories Beat Earnings Expectations And Analysts Now Have New Forecasts
Abbott Laboratories ( NYSE:ABT ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to...
© 2024 Yahoo. All rights reserved.